Compare · BGLC vs HUM
BGLC vs HUM
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM carries a market cap of $49.64B.
- Over the past year, BGLC is down 17.9% and HUM is down 18.2% - BGLC leads by 0.3 points.
- HUM has been more active in the news (13 items in the past 4 weeks vs 1 for BGLC).
- HUM has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Humana Inc.
- Price
- $2.31-10.47%
- $215.14+0.15%
- Market cap
- -
- $49.64B
- 1M return
- -10.47%
- +23.51%
- 1Y return
- -17.94%
- -18.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 13
- Recent ratings
- 0
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BGLC
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
- BioNexus Gene Lab Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events
Latest HUM
- SEC Form 3 filed by new insider Field Robert Stuart
- Humana Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CenterWell Introduces the Fulfillment Index, a New Measure of What It Means to Age Well
- SEC Form S-8 filed by Humana Inc.
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- On the Line for Lung Health: Telephone Training Helps COPD Patients Perfect Inhaler Use
- Tuesday Health Expands National Footprint With Humana Partnership to Advance Value-Based Palliative Care
- Humana Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Humana Elects Robert S. Field to Board of Directors
- Humana Goes Live with b.well to Deliver on Health Data Interoperability Commitments